A Multicenter, Randomized, Controlled, Open-label, Group-Sequential, Phase 3 Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation AntigenxCD3-Directed Bispecific Antibody Therapy
Latest Information Update: 27 May 2025
At a glance
- Drugs Immune globulin (Primary)
- Indications Infections
- Focus Therapeutic Use
- Sponsors Takeda
Most Recent Events
- 27 May 2025 New trial record